SK4222002A3 - Vaccine - Google Patents
Vaccine Download PDFInfo
- Publication number
- SK4222002A3 SK4222002A3 SK422-2002A SK4222002A SK4222002A3 SK 4222002 A3 SK4222002 A3 SK 4222002A3 SK 4222002 A SK4222002 A SK 4222002A SK 4222002 A3 SK4222002 A3 SK 4222002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- carrier
- hpv
- protein
- human papillomavirus
- antigens
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 15
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 21
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 19
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 19
- 239000002157 polynucleotide Substances 0.000 claims abstract description 19
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 16
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000011161 development Methods 0.000 claims abstract description 10
- 238000002255 vaccination Methods 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 6
- 230000003071 parasitic effect Effects 0.000 claims description 6
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 208000021145 human papilloma virus infection Diseases 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 101710125418 Major capsid protein Proteins 0.000 claims description 3
- 101800000874 Small capsid protein Proteins 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000005875 antibody response Effects 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 210000003300 oropharynx Anatomy 0.000 claims description 3
- 210000003899 penis Anatomy 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 210000001215 vagina Anatomy 0.000 claims description 3
- 210000003905 vulva Anatomy 0.000 claims description 3
- 101710121996 Hexon protein p72 Proteins 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 208000029211 papillomatosis Diseases 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 230000005740 tumor formation Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 101710135729 Major capsid protein L1 Proteins 0.000 abstract 1
- 241001631646 Papillomaviridae Species 0.000 description 8
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 6
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108700005307 Human papillomavirus HPV L1 Proteins 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010038707 Respiratory papilloma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000028802 immunoglobulin-mediated neutralization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903534A SE514982C2 (sv) | 1999-09-30 | 1999-09-30 | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
| PCT/SE2000/001808 WO2001023422A1 (en) | 1999-09-30 | 2000-09-19 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK4222002A3 true SK4222002A3 (en) | 2002-10-08 |
Family
ID=20417209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK422-2002A SK4222002A3 (en) | 1999-09-30 | 2000-09-19 | Vaccine |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1222200B1 (xx) |
| JP (1) | JP2003510064A (xx) |
| KR (1) | KR20020047195A (xx) |
| CN (1) | CN1373771A (xx) |
| AT (1) | ATE313559T1 (xx) |
| AU (1) | AU771481B2 (xx) |
| BR (1) | BR0014666A (xx) |
| CA (1) | CA2384723A1 (xx) |
| CZ (1) | CZ20021023A3 (xx) |
| DE (1) | DE60025016D1 (xx) |
| EE (1) | EE200200157A (xx) |
| HR (1) | HRP20020092A2 (xx) |
| HU (1) | HUP0202770A3 (xx) |
| IL (1) | IL148741A0 (xx) |
| MX (1) | MXPA02003328A (xx) |
| NO (1) | NO20020615L (xx) |
| NZ (1) | NZ516725A (xx) |
| PL (1) | PL355012A1 (xx) |
| RU (1) | RU2002111554A (xx) |
| SE (1) | SE514982C2 (xx) |
| SK (1) | SK4222002A3 (xx) |
| TR (1) | TR200200802T2 (xx) |
| WO (1) | WO2001023422A1 (xx) |
| YU (1) | YU22202A (xx) |
| ZA (1) | ZA200200886B (xx) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| CA2560487C (en) * | 2004-03-24 | 2013-01-29 | Merck & Co., Inc. | Optimized expression of hpv 52 l1 in yeast |
| DE102004036913A1 (de) * | 2004-07-16 | 2006-02-09 | Responsif Gmbh | Verwendung von Pentameren zur Herstellung eines Medikaments |
| CN1796403B (zh) * | 2004-12-22 | 2010-04-28 | 三峡大学 | 用于多型人乳头瘤病毒感染防治的多肽和疫苗 |
| CN100392084C (zh) * | 2006-03-13 | 2008-06-04 | 曾毅 | 含密码子优化型hpv16l1基因的重组腺病毒 |
| CN101914139B (zh) * | 2010-07-16 | 2012-11-21 | 四川大学 | 人类乳头瘤病毒(hpv)衣壳蛋白l1多肽及其制备与应用 |
| MY202196A (en) | 2017-06-23 | 2024-04-16 | Verimmune Inc | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses |
| CN113396155A (zh) | 2018-12-27 | 2021-09-14 | 维伊木恩股份有限公司 | 偶联病毒样颗粒及其作为抗肿瘤免疫重定向剂的用途 |
| WO2020163853A1 (en) * | 2019-02-08 | 2020-08-13 | Rensselaer Polytechnic Institute | A contraceptive vaccine based on the sperm-associated protein catsper |
| JP2023552040A (ja) | 2020-10-19 | 2023-12-14 | ヴェリミューン インコーポレイテッド | ウイルスにインスパイアされた組成物及びがんの治療のために同じものを使用して、既存の免疫応答をリダイレクトする方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE325875T1 (de) * | 1994-10-07 | 2006-06-15 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
| FR2768749A1 (fr) * | 1997-09-22 | 1999-03-26 | Inst Nat Sante Rech Med | Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique |
| DE19812941A1 (de) * | 1998-03-24 | 1999-10-07 | Medigene Ag | Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor |
-
1999
- 1999-09-30 SE SE9903534A patent/SE514982C2/sv not_active IP Right Cessation
-
2000
- 2000-09-19 PL PL00355012A patent/PL355012A1/xx not_active Application Discontinuation
- 2000-09-19 EP EP00966633A patent/EP1222200B1/en not_active Expired - Lifetime
- 2000-09-19 IL IL14874100A patent/IL148741A0/xx unknown
- 2000-09-19 SK SK422-2002A patent/SK4222002A3/sk unknown
- 2000-09-19 JP JP2001526572A patent/JP2003510064A/ja active Pending
- 2000-09-19 CZ CZ20021023A patent/CZ20021023A3/cs unknown
- 2000-09-19 AT AT00966633T patent/ATE313559T1/de not_active IP Right Cessation
- 2000-09-19 DE DE60025016T patent/DE60025016D1/de not_active Expired - Lifetime
- 2000-09-19 HU HU0202770A patent/HUP0202770A3/hu unknown
- 2000-09-19 MX MXPA02003328A patent/MXPA02003328A/es unknown
- 2000-09-19 NZ NZ516725A patent/NZ516725A/xx unknown
- 2000-09-19 TR TR2002/00802T patent/TR200200802T2/xx unknown
- 2000-09-19 RU RU2002111554/13A patent/RU2002111554A/ru unknown
- 2000-09-19 WO PCT/SE2000/001808 patent/WO2001023422A1/en active IP Right Grant
- 2000-09-19 CA CA002384723A patent/CA2384723A1/en not_active Abandoned
- 2000-09-19 EE EEP200200157A patent/EE200200157A/xx unknown
- 2000-09-19 BR BR0014666-8A patent/BR0014666A/pt not_active IP Right Cessation
- 2000-09-19 CN CN00812618A patent/CN1373771A/zh active Pending
- 2000-09-19 YU YU22202A patent/YU22202A/sh unknown
- 2000-09-19 AU AU76951/00A patent/AU771481B2/en not_active Ceased
- 2000-09-19 KR KR1020027004124A patent/KR20020047195A/ko not_active Application Discontinuation
-
2002
- 2002-01-29 HR HR20020092A patent/HRP20020092A2/hr not_active Application Discontinuation
- 2002-01-31 ZA ZA200200886A patent/ZA200200886B/en unknown
- 2002-02-08 NO NO20020615A patent/NO20020615L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0202770A3 (en) | 2004-07-28 |
| SE9903534L (sv) | 2001-03-31 |
| CN1373771A (zh) | 2002-10-09 |
| WO2001023422A1 (en) | 2001-04-05 |
| RU2002111554A (ru) | 2004-03-27 |
| HUP0202770A2 (hu) | 2002-12-28 |
| EP1222200A1 (en) | 2002-07-17 |
| CZ20021023A3 (cs) | 2002-07-17 |
| NZ516725A (en) | 2003-03-28 |
| IL148741A0 (en) | 2002-09-12 |
| NO20020615L (no) | 2002-05-29 |
| MXPA02003328A (es) | 2004-09-10 |
| SE9903534D0 (sv) | 1999-09-30 |
| PL355012A1 (en) | 2004-03-22 |
| AU7695100A (en) | 2001-04-30 |
| JP2003510064A (ja) | 2003-03-18 |
| HRP20020092A2 (en) | 2003-06-30 |
| TR200200802T2 (tr) | 2002-09-23 |
| YU22202A (sh) | 2005-06-10 |
| KR20020047195A (ko) | 2002-06-21 |
| BR0014666A (pt) | 2002-06-18 |
| NO20020615D0 (no) | 2002-02-08 |
| DE60025016D1 (de) | 2006-01-26 |
| CA2384723A1 (en) | 2001-04-05 |
| SE514982C2 (sv) | 2001-05-28 |
| EP1222200B1 (en) | 2005-12-21 |
| ZA200200886B (en) | 2003-03-26 |
| AU771481B2 (en) | 2004-03-25 |
| ATE313559T1 (de) | 2006-01-15 |
| EE200200157A (et) | 2003-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jochmus et al. | Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine | |
| EP0647140B1 (en) | Papillomavirus vaccines | |
| Suzich et al. | Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. | |
| Christensen et al. | Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies | |
| Karanam et al. | Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection | |
| Campo et al. | Papillomavirus prophylactic vaccines: established successes, new approaches | |
| US5874089A (en) | Protecting against canine oral papillomavirus (copy) | |
| Fligge et al. | Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33 | |
| Roden et al. | Preventative and therapeutic vaccines for cervical cancer | |
| Jagu et al. | A multimeric L2 vaccine for prevention of animal papillomavirus infections | |
| Palmer et al. | Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer | |
| SK4222002A3 (en) | Vaccine | |
| Ghim et al. | Equine papillomavirus type 1: complete nucleotide sequence and characterization of recombinant virus-like particles composed of the EcPV-1 L1 major capsid protein | |
| JP2002516291A (ja) | パピローマウイルス・ウイルス様粒子による経口免疫感作 | |
| AU2003232951B2 (en) | Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles. | |
| Müller et al. | A long way: history of the prophylactic papillomavirus vaccine | |
| Tindle | Immunomanipulative strategies for the control of human papillomavirus associated cervical disease | |
| US20040146531A1 (en) | Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells | |
| Ellis | The new generation of recombinant viral subunit vaccines | |
| Sapp et al. | Synthesis, properties and applications of papillomavirus-like particles | |
| Deng et al. | The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro | |
| WO1996033737A1 (en) | Peptide-based vaccine against papillomavirus infection | |
| Kazaks et al. | 11 Papillomavirus-Derived Virus-Like Particles | |
| Jansen | HPV Vaccines for Protection Against Infection | |
| Christensen | Ricai Han, Nancy M. Cladel, Cynthia A. Reed, Xuwen Peng |